Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Apoptosis and Antibodies

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5159
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Apoptosis and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Apoptosis and Antibodies.

    To find out more about Triple Analysis: Melanoma, Apoptosis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Apoptosis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
3SBio
A&G Pharmaceutical
AB Science
Abbott
AbbVie
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actelion
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Aileron Therapeutics
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Alnylam
AlphaVax
ALSP
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
AngioChem
Antisense Pharma
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Basilea Pharmaceutica
Bayer
Berkeley Lab
Bio-Medisinsk Innovasjon
BioAlliance Pharma
BioAxone
Biocad
Biocon
Biogen Idec
BioInvent
Biokine Therapeutics
Biolex
BioLineRx
Biomas
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celera
Celgene
Celldex Therapeutics
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
ChemoCentryx
Chlorogen
Chroma Therapeutics
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
CombinatoRx
Coronado Biosciences
Cosmo Pharmaceuticals
Critical Outcome Technologies
CSL
CuraGen
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
DNAVEC
Dompe
Dong-A
Dr Reddy’s
Dyax
Eisai
Elan
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Ergon Pharmaceuticals
Erimos
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Flamel Technologies
Fusion Antibodies
Galaxy Biotech
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Genta
GenVec
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
GPC Biotech
Gradalis
Green Cross
Harbor BioSciences
Hawthorn Pharmaceuticals
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intradigm
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kaketsuken
KaloBios
Kalypsys
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
MAT Biopharma
Meda
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Mycenax
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
NIH
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
Oasmia
Oncalis
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
Panacea
PanaGin
PanGenetics
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaMar
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
QLT
Ramot
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Rosetta Genomics
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sareum
SBI Biotech
Scancell
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Shanghai CP Guojian
Shenogen
Shire
Sigma-Tau
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spirogen
SRI International
Stainwei Biotech
Sunesis
Sunol Molecular
SuperGen
SuppreMol
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Synta Pharmaceuticals
Tactic Pharma
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
TeGenero
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
UMN Pharma
United Therapeutics
Vaccinex
Wakunaga
ValiRx
VasGene Therapeutics
VBL Therapeutics
Vectura
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
Viragen
Viralytics
ViroTarg
Viventia Biotech
VM Discovery
WntResearch
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
YM BioSciences
York Pharma
Zenotech
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
adecatumumab
AEB071
AEG-35156
aflibercept
agatolimod
AGS-1C4D4
ALD-518
aldesleukin
alemtuzumab
ALT-801
alvocidib
amatuximab
AME-133
AMG-386
APG-101
APO-866
ARQ-197
ARRY-438162
AS-101
AS-1411
astuprotimut-r
Auto TAG vaccine
AV-299
axitinib
bardoxolone methyl
belimumab
belinostat
bevacizumab
BHQ880
blinatumomab
BMS-663513
BMS-936558
bortezomib
bosutinib
brentuximab vedotin
BT-062
Buparlisib
BZL-101
Cabozantinib
canfosfamide hydrochloride
carlumab
catumaxomab
CB-10-01
CDX-1307
CDX-1401
cenersen
cetuximab
cilengitide
cintredekin besudotox
cixutumumab
CMAB302
CMAB304
conatumumab
cositecan
crolibulin
CT-011
dalotuzumab
daratumumab
dasatinib
decitabine
denenicokin
denileukin diftitox
denosumab
dinaciclib
dovitinib lactate
dulanermin
E7449
elotuzumab
EMD-273063
EMD525797
endostatin
entinostat
enzastaurin hydrochloride
epirubicin
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
fosbretabulin tromethamine
fresolimumab
galiximab
ganetespib
ganitumab
gataparsen
gefitinib
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
golvatinib
GS-6634
GSK-1120212
GSK-2118436
GT-111
GV-1001
GVAX
HE-3235
Hi-8 MEL
histamine dihydrochloride
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
idronoxil
imatinib mesilate
imetelstat
INCB-24360
inotuzumab ozogamicin
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
IPH-2102
ipilimumab
iratumumab
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
L19-TNFalpha
Lambrolizumab
LEE-011
lenvatinib
lestaurtinib
LGX818
lintuzumab
LIP-131I
LipoVIL12
litronesib
lonaprisan
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDX-1379
MEDI-551
MEDI-573
MetXia
MGN-1601
milatuzumab
milatuzumab-doxorubicin
MKC-1
MKC-1106-MT
MM-111
MM-121
mocetinostat
mogamulizumab
MOR202
MOR208
MORAb-004
motexafin gadolinium
moxetumomab pasudotox
naptumomab estafenatox
natalizumab
navitoclax
necitumumab
nilotinib
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
ofatumumab
olaratumab
ON-01910
onartuzumab
Oncohist
OncoVAX
Onyvax-105
oregovomab
P276-00
panitumumab
panobinostat
PAT-SC1
PBI-1402
PCI-24781
peginterferon alfa-2b
perifosine
pertuzumab
PF-4856884
pimasertib
plitidepsin
poly-ICLC
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
Reditux
retaspimycin
RG-7160
rhIFN-alpha
ridaforolimus
rilotumumab
rintatolimod
rituximab
robatumumab
romiplostim
sagopilone
samalizumab
SAR-3419
sargramostim
SCIB-1
seliciclib
selumetinib
siltuximab
sotatercept
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
Sym-004
talminogene laherparepvec
Tenarad
terameprocol
tesetaxel
thalidomide
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
tocilizumab
trabedersen
TRC-105
tremelimumab
triciribine phosphate
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
velimogene aliplasmid
veliparib
veltuzumab
vemurafenib
verubulin
vinflunine ditartrate
vitespen
volasertib
volociximab
vosaroxin
XL-147
XL-647
YM-155
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Apoptosis and Antibodies.
    To find out more about Triple Analysis: Melanoma, Apoptosis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Apoptosis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Prostate Cancer. Learn More


Triple Analysis: Colorectal Cancer, Leukemia and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


Lymphoma - A Therapeutic & Competitive Insight
Gain insight into the current challenges and commercial opportunities associated with lymphoma therapy Learn More


Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer. Learn More